Pharm-Rx Pantoprazole Sodium USP

Product families

Other characteristics

Certifications & Compliance

United States Pharmacopeia (USP)

Markets

Healthcare & Pharma

Defination

Pantoprazole Sodium contains NLT 98.0% and NMT 102.0% of pantoprazole sodium (C₁₆H₁₄F₂N₃NaO₄S), calculated on the anhydrous basis.

Technology

Pharmaceuticals & Nutraceuticals

FDA Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Storage Information

Preserve in well-closed, light-resistant containers. Store at room temperature.

USP Reference Standards

USP Pantoprazole Sodium RS; USP Pantoprazole Related Compound A RS; 5-(Difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl) methylsulfonyl]-1H-benzimidazole.▲ (USP 1-Dec-2023) C₁₆H₁₅F₂N₃O₅S 399.37; USP Pantoprazole Related Compound B RS; 5-(Difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl) methylthio]-1H-benzimidazole.▲ (USP 1-Dec-2023) C₁₆H1₅F₂N₃O₃S 367.37; USP Pantoprazole Related Compound C RS; 5-(Difluoromethoxy)-1H-benzimidazole-2-thiol. C₈H₆F₂N₂OS 216.21; USP Pantoprazole Related Compounds D and F Mixture RS; USP Pantoprazole Related Compound E RS; 6,6′-Bis(difluoromethoxy)-2,2′-bis[[(3,4- dimethoxypyridin-2-yl)methyl]sulfinyl]-1H,1′H-5,5′- bibenzimidazole. C₃₂H₂₈F₄N₆O₈S₂ 764.72

Show in full

Certifications and Compliance

United States Pharmacopeia (USP)